1
|
Ji L, Song T, Ge C, Wu Q, Ma L, Chen X, Chen T, Chen Q, Chen Z, Chen W. Identification of bioactive compounds and potential mechanisms of scutellariae radix-coptidis rhizoma in the treatment of atherosclerosis by integrating network pharmacology and experimental validation. Biomed Pharmacother 2023; 165:115210. [PMID: 37499457 DOI: 10.1016/j.biopha.2023.115210] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 07/29/2023] Open
Abstract
OBJECTIVE This study aims at investigating the potential targets and functional mechanisms of Scutellariae Radix-Coptidis Rhizoma (QLYD) against atherosclerosis (AS) through network pharmacology, molecular docking, bioinformatic analysis and experimental validation. METHODS The compositions of QLYD were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and literature, where the main active components of QLYD and corresponding targets were identified. The potential therapeutic targets of AS were excavated using the OMIM database, DrugBank database, DisGeNET database, CTD database and GEO datasets. The protein-protein interaction (PPI) network of common targets was constructed and visualized by Cytoscape 3.7.2 software. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis were performed to analyze the function of core targets in the PPI network. Molecular docking was carried out using AutoDockTools, AutoDock Vina, and PyMOL software to verify the correlation between the main components of QLYD and the core targets. Mouse AS model was established and the results of network pharmacology were verified by in vivo experiments. RESULTS Totally 49 active components and 225 corresponding targets of QLYD were obtained, where 68 common targets were identified by intersecting with AS-related targets. Five hub genes including IL6, VEGFA, AKT1, TNF, and IL1B were screened from the PPI network. GO functional analysis reported that these targets had associations mainly with cellular response to oxidative stress, regulation of inflammatory response, epithelial cell apoptotic process, and blood coagulation. KEGG pathway analysis demonstrated that these targets were correlated to AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, IL-17 signaling pathway, MAPK signaling pathway, and NF-kappa B signaling pathway. Results of molecular docking indicated good binding affinity of QLYD to FOS, AKT1, and TNF. Animal experiments showed that QLYD could inhibit inflammation, improve blood lipid levels and reduce plaque area in AS mice to prevent and treat AS. CONCLUSION QLYD may exert anti-inflammatory and anti-oxidative stress effects through multi-component, multi-target and multi-pathway to treat AS.
Collapse
Affiliation(s)
- Lingyun Ji
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China
| | - Ting Song
- Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250011, China
| | - Chunlei Ge
- Department of Respiratory Medicine, Linyi Tradition Chinese Medical Hospital, Linyi, Shandong Province 276600, China
| | - Qiaolan Wu
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China
| | - Lanying Ma
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China
| | - Xiubao Chen
- Department of Geriatric Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250011, China
| | - Ting Chen
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China
| | - Qian Chen
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China
| | - Zetao Chen
- Department of Geriatric Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250011, China; Subject of Integrated Chinese and Western Medicine,Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, China.
| | - Weida Chen
- Department of Geriatric Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250011, China.
| |
Collapse
|
2
|
Mobile RZ, Mendes MC, Machado-Souza C, Queiroz PDM, Bonfim CMS, Torres-Pereira CC, Schussel JL. IL17A and IL17RA gene polymorphisms in Fanconi anemia. Braz Oral Res 2023; 37:e012. [PMID: 36790253 DOI: 10.1590/1807-3107bor-2023.vol37.0012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 08/18/2022] [Indexed: 02/16/2023] Open
Abstract
Fanconi anemia is a rare autosomal recessive disease. In this disease, cytokine pathways can induce the bone marrow failure that is observed in individuals with Fanconi anemia. Interleukin IL-17 exhibits a protective effect in organisms because it induces neutrophil recruitment and shows a pathological role in several models of autoimmune diseases, periodontal disease, cancer, allograft rejection, and graft versus host disease. Polymorphisms in the IL17A and IL17RA genes were evaluated from DNA in saliva, comparing individuals with or without Fanconi anemia, using models of genotypic transmission (additive, dominant, and recessive). Polymorphisms in the IL17A and IL17RA genes (rs2241044 [C allele], rs879577 [C allele], rs9606615 [T allele], and rs2241043 [C allele]) were risk factors for developing Fanconi anemia. We also performed an analysis of gene markers with clinical variables in the Fanconi group. Polymorphisms in the IL17A gene (rs3819025 [A allele] and rs2275913 [G allele], respectively) were associated with an age of less than 20 years (p = 0.026; RP 0.65) and the female sex (p = 0.043; RP 0.88). The IL17RA gene was also associated with age and the presence of leukoplakia (a potentially malignant oral disorder). An age of less than 20 years was associated with rs917864 (T allele; p = 0.036; RP 0.67). The presence of leukoplakia was associated with rs17606615 (T allele; p = 0.042; RP 0.47). To our knowledge, this is the first study that associates IL17A and IL17RA gene polymorphisms with Fanconi anemia and examines rs2241044 polymorphisms in scientific literature thus far.
Collapse
Affiliation(s)
- Rafael Zancan Mobile
- Universidade Federal do Paraná - UFPR, Post Graduate Program in Dentistry, Department of Stomatology, Curitiba, PR, Brazil
| | - Monalisa Castilho Mendes
- Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Postgraduation Program in Biotechnology Applied in Health of Children and Adolescent, Curitiba, PR, Brazil
| | - Cleber Machado-Souza
- Instituto de Pesquisa Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Postgraduation Program in Biotechnology Applied in Health of Children and Adolescent, Curitiba, PR, Brazil
| | - Priscila de Mattos Queiroz
- Universidade Federal do Paraná - UFPR, School of Dentistry, Department of Stomatology, Curitiba, PR, Brazil
| | - Carmem Maria Sales Bonfim
- Universidade Federal do Paraná - UFPR, Complexo Hospital de Clínicas, Bone Marrow Transplantation Program, Curitiba, PR, Brazil
| | | | - Juliana Lucena Schussel
- Universidade Federal do Paraná - UFPR, Post Graduate Program in Dentistry, Department of Stomatology, Curitiba, PR, Brazil
| |
Collapse
|
3
|
Liberalesso VYSW, Azevedo MLV, Malaquias MAS, de Paula CBV, Nagashima S, de Souza DG, Neto PC, Gouveia KO, Biscaro LC, Giamberardino ALG, Gonçalves GT, Kondo TTS, Raboni SM, Weiss I, Machado-Souza C, de Noronha L. The role of IL17 and IL17RA polymorphisms in lethal pandemic acute viral pneumonia (Influenza A virus H1N1 subtype). SURGICAL AND EXPERIMENTAL PATHOLOGY 2023; 6:1. [PMCID: PMC9907201 DOI: 10.1186/s42047-023-00126-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023] Open
Abstract
Background The cytokines play an essential role in acute inflammatory processes, and the IL-17 may be responsible for ambiguous aspects, and the correlation with genetic polymorphisms could improve the search for this critical biomarker. Thus, this study aimed to evaluate the IL-17A and IL-17RA tissue expression and the polymorphisms that codified these proteins in a population that died of pandemic Influenza A virus H1N1 subtype compared to a non-pandemic Influenza virus population. Methods Necropsy lung samples immunohistochemistry was performed to assess the presence of IL-17A and IL-17RA in the pulmonary tissue. Eight single nucleotide polymorphisms were genotyped using TaqMan® technology. Results The Influenza A H1N1 pandemic group had higher tissue expression of IL-17A, higher neutrophil recruitment and shorter survival time between admission and death. Three single nucleotide polymorphisms conferred risk for pandemic influenza A H1N1, the AA genotype of rs3819025 G/A, the CC genotype of rs2241044 A/C, and the TT genotype of rs 2,241,043 C/T. Conclusions One IL17A polymorphism (rs381905) and two IL17RA polymorphisms (rs2241044 and rs2241043) represented biomarkers of worse prognosis in the population infected with pandemic influenza A H1N1. The greater tissue expression of IL-17A shows a Th17 polarization and highlights the aggressiveness of the pandemic influenza virus with its duality in the protection and pathogenesis of the pulmonary infectious process.
Collapse
Affiliation(s)
| | - Marina Luise Viola Azevedo
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Mineia Alessandra Scaranello Malaquias
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Caroline Busatta Vaz de Paula
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Seigo Nagashima
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Daiane Gavlik de Souza
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Plínio Cézar Neto
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Kauana Oliveira Gouveia
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Larissa Cristina Biscaro
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Ana Luisa Garcia Giamberardino
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Gabrielle Tasso Gonçalves
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Thais Teles Soares Kondo
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| | - Sonia Maria Raboni
- grid.411078.b0000 0004 0502 3690Laboratory of Virology, Hospital de Clínicas, Universidade Federal Do Paraná, Curitiba, Brazil
| | - Isabelle Weiss
- Postgraduation Program in Biotechnology Applied in Health of Children and Adolescent, Faculdades Pequeno Príncipe, Curitiba, Brazil
| | - Cleber Machado-Souza
- Postgraduation Program in Biotechnology Applied in Health of Children and Adolescent, Faculdades Pequeno Príncipe, Curitiba, Brazil
| | - Lucia de Noronha
- grid.412522.20000 0000 8601 0541Postgraduation Program in Health Sciences of School of Medicine, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil
| |
Collapse
|
4
|
Lee Y, Singh J, Scott SR, Ellis B, Zorlutuna P, Wang M. A Recombinant Dimethylarginine Dimethylaminohydrolase-1-Based Biotherapeutics to Pharmacologically Lower Asymmetric Dimethyl Arginine, thus Improving Postischemic Cardiac Function and Cardiomyocyte Mitochondrial Activity. Mol Pharmacol 2022; 101:226-235. [PMID: 35042831 PMCID: PMC11033929 DOI: 10.1124/molpharm.121.000394] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 01/16/2022] [Indexed: 11/22/2022] Open
Abstract
High serum levels of asymmetric dimethyl arginine (ADMA) are associated with cardiovascular disease and mortality. Pharmacological agents to specifically lower ADMA and their potential impact on cardiovascular complications are not known. In this study, we aimed to investigate the effect of specific lowering of ADMA on myocardial response to ischemia-reperfusion injury (I/R) and direct effects on cardiomyocyte function. Effects of recombinant dimethylarginine dimethylaminohydrolase (rDDAH)-1 on I/R injury were determined using isolated mouse heart preparation. Respiration capacity and mitochondrial reactive oxygen species (ROS) generation were determined on mouse cardiomyocytes. Our results show that lowering ADMA by rDDAH-1 treatment resulted in improved recovery of cardiac function and reduction in myocardial infarct size in mouse heart response to I/R injury (control 22.24 ±4.60% versus rDDAH-1 15.90 ±4.23%, P < 0.01). In mouse cardiomyocytes, rDDAH-1 treatment improved ADMA-induced dysregulation of respiration capacity and decreased mitochondrial ROS. Furthermore, in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes with impaired contractility under hypoxia and high ADMA, rDDAH-1 treatment improved recovery and beating frequency (P < 0.05). rDDAH-1 treatment selectively modified I/R-induced myocardial cytokine expression, resulting in reduction in proinflammatory cytokine IL-17A (P < 0.001) and increased expression of anti-inflammatory cytokines IL-10 and IL-13 (P < 0.01). Further in vitro studies showed that IL-17A was the predominant and common cytokine modulated by ADMA-DDAH pathway in heart, cardiomyocytes, and endothelial cells. These studies show that lowering ADMA by pharmacological treatment with rDDAH-1 reduced I/R injury, improved cardiac function, and ameliorated cardiomyocyte bioenergetics and beating activity. These effects may be attributable to ADMA lowering in cardiomyocytes and preservation of cardiomyocyte mitochondrial function. SIGNIFICANCE STATEMENT: The pathological role of asymmetric dimethyl arginine (ADMA) has been demonstrated by its association with cardiovascular disease and mortality. Currently, pharmacological drugs to specifically lower ADMA are not available. The present study provides the first evidence that lowering of ADMA by recombinant recombinant dimethylarginine dimethylaminohydrolase (rDDAH)-1 improved postischemic cardiac function and cardiomyocyte bioenergetics and beating activity. Our studies suggest that lowering of ADMA by pharmacologic treatment offers opportunity to develop new therapies for the treatment of cardiovascular and renal disease.
Collapse
Affiliation(s)
- Young Lee
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Jaipal Singh
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Susan R Scott
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Bradley Ellis
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Pinar Zorlutuna
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Meijing Wang
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (J.S.); Department of Surgery, Indiana University, School of Medicine, Indianapolis, Indiana (S.R.S., M.W.); Bioengineering Graduate Program (B.E., P.Z.) and Aerospace and Mechanical Engineering Department (P.Z.), University of Notre Dame, Notre Dame, Indiana; and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| |
Collapse
|
5
|
Coto E, Pascual I, Avanzas P, Cuesta-Lavona E, Lorca R, Martín M, Vázquez-Coto D, Díaz-Corte C, Morís C, Rodríguez-Reguero J, Gómez J. IL17RA in early-onset coronary artery disease: Total leukocyte transcript analysis and promoter polymorphism (rs4819554) association. Cytokine 2020; 136:155285. [PMID: 32950026 DOI: 10.1016/j.cyto.2020.155285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Revised: 09/03/2020] [Accepted: 09/04/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND AND AIMS The interleukin-17 (IL-17) pathway would play an important role in the pathogenesis of atherosclerosis and coronary-artery disease (CAD). The IL-17 inflammatory mediators are expressed by Th17 cells, a group of CD4 + leukocytes that infiltrate the vascular milieu and are pivotal in the origin, progression, stability and rupture of the atherosclerotic lesion. Cigarette smoke compounds stimulated the expression of IL-17 and IL-17-receptors. In atherogenic mice models the deficiency of IL-17RA resulted in a reduction of the atherosclerotic lesion size and leukocyte infiltrate. We hypothesised that common the IL-17RA transcript might be differential expressed in the leukocytes from CAD patients and healthy individuals. METHODS The relative amount of the IL-17RA to ACTB transcript was determined in total leukocytes of 55 patients and 50 controls, all smokers. We genotyped the IL-17RA rs48195554 promoter polymorphisms in 390 healthy controls and 450 early-onset CAD patients. RESULTS Patients showed significantly higher mean IL-17RA normalised transcript value than controls (p < 0.001). For the IL-17RA rs48195554 promoter polymorphisms, IL-17RA G-carriers showed higher transcript values. However, allele and genotype frequencies did not differ between patients and controls and we thus excluded a significant association with CAD. CONCLUSIONS The higher levels of the IL-17RA transcript among CAD-patients was in agreement with a role for the IL-17 pathway in the pathogenesis of coronary atherosclerosis.
Collapse
Affiliation(s)
- Eliecer Coto
- Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Departamento Medicina, Universidad de Oviedo, Oviedo, Spain; Red de Investigación Renal (REDINREN), Madrid, Spain.
| | - Isaac Pascual
- Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain
| | - Pablo Avanzas
- Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain
| | - Elías Cuesta-Lavona
- Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain
| | - Rebeca Lorca
- Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain
| | - María Martín
- Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain
| | | | - Carmen Díaz-Corte
- Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Departamento Medicina, Universidad de Oviedo, Oviedo, Spain; Red de Investigación Renal (REDINREN), Madrid, Spain; Nefrología, Hospital Universitario Central Asturias, Oviedo, Spain
| | - César Morís
- Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain; Departamento Medicina, Universidad de Oviedo, Oviedo, Spain
| | | | - Juan Gómez
- Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain
| |
Collapse
|
6
|
Wu YJ, Lee YN, Wu TW, Chou CL, Wang LY. Common Genetic Variants on Bone Morphogenetic Protein Receptor Type IB (BMPR1B) Gene Are Predictive for Carotid Intima-Media Thickness. Circ J 2019; 83:749-756. [PMID: 30713213 DOI: 10.1253/circj.cj-18-1046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND Bone morphogenetic proteins (BMP) 2 and 4 are implicated in the development of atherosclerosis. However, the relationships between the proteins, their main receptors and carotid intima-media thickness (cIMT), a predictive preclinical phenotype of atherosclerosis, have not been established. Methods and Results: We screened and validated the relationships of single-nucleotide polymorphisms (SNPs) on BMP2, BMP4, BMPR1A, BMPR1B, and BMPR2 with thicker cIMT by 2 independent case-control studies that used different subject selection methods. Among 200 screened SNPs, 12 on BMPR1B were regarded as candidate genetic markers (P-value <5.0×10-4). After combining the discovery and validation studies and adjusting for traditional cardiovascular risk factors, rs4456963*G, rs4235438*T, rs2522530*T, and rs3796433*C showed significant higher odds ratios (ORs) of having thicker cIMT (adjusted ORs: 1.50-1.56; all P-values <2.5×10-4). Multivariate analyses showed that rs4456963 and rs3796433 were significantly independent determinants of cIMT thickening. The corresponding multivariate-adjusted ORs for rs4456963*G and rs3796433*C alleles were 1.50 (95% confidence interval (CI): 1.22-1.84) and 1.50 (95% CI: 1.23-1.82), respectively. Interaction between rs4456963 and rs3796433 was evident by the significantly higher OR (8.16, 95% CI: 3.12-21.3) for subjects with the GG-CC genotype. The rs4456963*G and rs3796433*C showed positively linear trends with severity of carotid atherosclerosis. CONCLUSIONS We identified 2 SNPs on BMPR1B showing significantly independent correlations with thicker cIMT. The study provides invaluable evidence supporting that BMPR1B is closely related to carotid atherosclerosis and a potential target for the development of therapeutic agents for atherosclerotic disease.
Collapse
Affiliation(s)
- Yih-Jer Wu
- Department of Medicine, Mackay Medical College.,Institute of Biomedical Sciences, Mackay Medical College.,Cardiovascular Center, Department of Internal Medicine, MacKay Memorial Hospital.,Department of Medical Research, MacKay Memorial Hospital
| | - Yi-Nan Lee
- Department of Medical Research, MacKay Memorial Hospital
| | - Tzu-Wei Wu
- Department of Medicine, Mackay Medical College
| | - Chao-Liang Chou
- Department of Medicine, Mackay Medical College.,Department of Neurology, Mackay Memorial Hospital
| | - Li-Yu Wang
- Department of Medicine, Mackay Medical College.,Institute of Biomedical Sciences, Mackay Medical College
| |
Collapse
|